Telomir Pharmaceuticals (TELO) Stock Price, News & Analysis

Company Overview

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

Key Stats

• Today's Range: $4.10 to $4.90
• 50-Day Range: $3.31 to $7.84
• 52-Week Range: $3.11 to $20.72
• Volume: 131,504 shs
• Average Volume: 82,947 shs
• Market Capitalization: $125.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TELO Stock Analysis - Frequently Asked Questions

How have TELO shares performed this year?

Telomir Pharmaceuticals' stock was trading at $5.00 at the beginning of the year. Since then, TELO stock has decreased by 15.2% and is now trading at $4.24.
View the best growth stocks for 2024 here.

When did Telomir Pharmaceuticals IPO?

Telomir Pharmaceuticals (TELO) raised $7 million in an initial public offering (IPO) on Friday, February 9th 2024. The company issued 1,000,000 shares at a price of $7.00 per share. Kingswood Investments served as the underwriter for the IPO.

Who are Telomir Pharmaceuticals' major shareholders?

Top institutional investors of Telomir Pharmaceuticals include Geode Capital Management LLC (0.81%), Suncoast Equity Management (0.17%), State Street Corp (0.12%) and Barclays PLC (0.02%).

How do I buy shares of Telomir Pharmaceuticals?

Shares of TELO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Today: 11/23/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 4/04/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TELO
• Previous Symbol: NASDAQ:TELO
• CUSIP: N/A
• CIK: 1971532
• Web: telomirpharma.com
• Phone: (737)-289-0835
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-13,070,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,087.92%
• Return on Assets: -806.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.74
• Quick Ratio: 1.74

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.01 per share
• Price / Book: 424.00

Miscellaneous

• Outstanding Shares: 29,610,000
• Free Float: N/A
• Market Cap: $125.55 million
• Optionable: N/A
• Beta: N/A